Serum 132--microglobulin (~2-m) levels were measured in oral carcinoma patients and compared with normal healthy controls. It was observed that there was a significant rise in serum 132-microglobulin in oral carcinoma i~atients. Progressively higher values were obtained as the cancer advanced clinically. Therefore the estimation of serum 132-microglobulin may be useful as one of a battery of tests in the assessment of oral carcinoma patients.
INTRODUCTION

MATERIALS AND METHODS
In oral carcinoma, the study of tumor markers have been limited. Several tumor markers (Ferritin, Nacetyl neuraminic acid, phosphohexose isomerase, CEA) with clinical promise need further evaluation. One such tumor marker is serum 132-mlcr~176 (132-m). It was first described and isolated from the urine of patients with tubular proteinurias by Berggard and Beam in 1968 (1) . 132-micr~176 is a low molecular weight, 11600 Dalton protein found on the surface of all cells except erythrocytes. It was also shown to occur in small quantities in normal human urine, plasma and cerebrospinal fluid (1) . This protein is the light or 13-chain of the human leucocyte antigen (HLA). It exists in two main forms free and non-covalently linked to the HLA antigens, forming an invariant part of the HLA molecules. The serum 132 -microglobulin is in the free form (2) . It consists of a single polypeptide chain with one intrachain disulfide bridge. It does not contain carbohydrate (1) .
Increased 132-m levels have been reported in patients with oral cancer as well (3, 4, 5) The mean value of oral carcinoma patients was significantly nigher than that in control group. As the stage of oral cancer advanced, the serum level of 132 -m was increased as shown in the table 1. In this study, the serum level of 2.4mg/L was taken as the cut off value (6). Only 20 out of 30 oral cancer patients had elevated levels of serum 132 -m and thus the sensitivity of 65.5%. The test showed an abnormal result in only I out of 20 of healthy controls and thus the specificity of 95.2%, positive predictive value 95%, negative predictive value of 66.6%, and efficiency of the test 78%.
DISCUSSION
The 92 -microglobulin which is synthesized and secreted by lymphocytes as well as most other nucleated cells, is an intrinsic part of histocompatibility antigen. It has a low molecular weight and rapid turnover (1) . Elevated levels of 132 -m have been observed in a variety of patients mostly with advanced malignancy and other disease states (7, 8, 9) . The concentration of serum 1~2 -m was found to be increased in cases of various non neoplastic disorders like renal diseases (1, 10) , acquired immunodeficiency syndrome (11), psoriasis (12), non-Hodgkin's lymphoma (13), chronic myelogenous leukemias (14). Hence elevated levels of 13~ -m is not specific to oral carcinoma because it is altered in various non neoplastic and other neoplastic conditions.
In the present study the serum 132 -m values were increased in oral cancer group, when compared with controls, and this is statistically significant (p<0.05) ( Table 1 ). The increased levels of 132 -m may be due to increased production or impaired excretion. However. as the patients in this present study did not have any disorder of renal function or other systemic ailments, & other malignancies, the increase in serum 132-m appears to be a true phenomenon due to the malignant process involving oral carcinoma. The fact that 132 -m values are elevated in the serum of subjects with oral malignancy is in agreement with reports (3, 4, 5) .
The mechanism of increase in 132 -m levels in malignancies is not known but various possible hypothesis for the increased serum levels have been put forward. The 132 -m is a cell membrane constituent along with the HLA chain, so an accelerated membrane turnover or accelerated cell division could increase the shedding of 132-m (15). The ability of the carcinoma cells to produce a higher concentration of 13~ -m than the non-neoplastic cells may be due to either active synthesis or increased cell breakdown or both (9).
As the predictive value of this estimation was found to be 95% and that of specificity of the test as 95.2%, this study confirms the results of other investigators in oral carcinoma. However as stated above it lacks specificity for oral carcinoma as an individual marker because it is elevated in other diseases also. Hence further studies are necessary to find out whether serum 132-m would be of help in clinical diagnosis. 
